10-12 September 2018 //  Lancaster Royal Hotel, London


David Spencer

Dr David Spencer

Chief Scientific Officer, Bellicum Pharmaceuticals

David Spencer joined Bellicum in 2012 as Chief Scientific Officer. Dr. Spencer is an inventor of CID technology, and helped develop the first clinical applications of the technology, including CaspaCIDe®, and GoCAR-T® technologies that are now advancing in human clinical trials. Prior to joining Bellicum, he served as Professor and Vice Chairman of Pathology & Immunology, Baylor College of Medicine, during which time he was a scientific advisor to the Company. Dr. Spencer oversees a robust research program focused on CID clinical applications and supports clinical development of CID-enabled products. He earned his Ph.D. at Massachusetts Institute of Technology and was a postdoctoral fellow at Stanford University.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad